Compare ALVO & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALVO | SLBT |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Luxembourg | Taiwan |
| Employees | N/A | 20 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 942.1M |
| IPO Year | 2021 | 2025 |
| Metric | ALVO | SLBT |
|---|---|---|
| Price | $5.85 | $1.53 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 972.6K | 79.0K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $1.50 |
| 52 Week High | $9.05 | $6.25 |
| Indicator | ALVO | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 72.69 | 26.81 |
| Support Level | $3.10 | N/A |
| Resistance Level | N/A | $3.36 |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 81.47 | 9.21 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.